Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives.

The deal with Alector marks one of Roche’s most high-profile Parkinson’s deals in the past decade. Credit: JitendraJadhav/Shutterstock.com. Roche is paying up to ...

CSL and Alentis will work together to progress antifibrotic drug, lixudebart across multiple rare kidney and liver diseases.

AstraZeneca has opened a new global strategic R&D facility in Massachusetts, US, as part of an investment of more than $1bn in the state.

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, as pharma explores its role on treating ophthalmic conditions.

The US FDA has approved an expanded indication for Lilly's Jaypirca as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.

Illustration of New Albany International Business Park. Credit: Bayer AG. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and manufacturing in the ...

Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.

Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.

Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.

Camzyos was initially approved by the FDA in 2022 for adult patients with symptomatic NYHA class II-III oHCM. Credit: NMK-Studio / Shutterstock.com. The US Food and Drug Administration (FDA) has ...

BioMarin will screen and evaluate the computational outputs, with the objective of advancing selected candidates into preclinical testing. Credit: agustin.photo / Shutterstock.com. BioMarin ...